FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115432999> ?p ?o ?g. }

• W2115432999 endingPage "5387" @default.
• W2115432999 startingPage "5381" @default.
• W2115432999 abstract "Purpose The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS). Patients and Methods Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m 2 , respectively; n = 510) or TC (75 and 600 mg/m 2 , respectively; n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor–positive disease, were administered after completion of chemotherapy. Results Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was significantly superior for TC compared with AC (86% v 80%, respectively; hazard ratio [HR] = 0.67; 95% CI, 0.50 to 0.94; P = .015). Overall survival rates for TC and AC were 90% and 87%, respectively (HR = 0.76; 95% CI, 0.52 to 1.1; P = .13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the TC arm; more nausea and vomiting occurred on the AC arm as well as one incident of congestive heart failure. Conclusion At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC." @default.
• W2115432999 created "2016-06-24" @default.
• W2115432999 creator A5002951950 @default.
• W2115432999 creator A5003827285 @default.
• W2115432999 creator A5008682252 @default.
• W2115432999 creator A5010188774 @default.
• W2115432999 creator A5015961133 @default.
• W2115432999 creator A5020192186 @default.
• W2115432999 creator A5028916394 @default.
• W2115432999 creator A5029811877 @default.
• W2115432999 creator A5030497065 @default.
• W2115432999 creator A5042123072 @default.
• W2115432999 creator A5044957566 @default.
• W2115432999 creator A5047894550 @default.
• W2115432999 creator A5059365988 @default.
• W2115432999 creator A5065675425 @default.
• W2115432999 creator A5068051080 @default.
• W2115432999 creator A5068970824 @default.
• W2115432999 creator A5071432873 @default.
• W2115432999 creator A5076687894 @default.
• W2115432999 creator A5078164972 @default.
• W2115432999 creator A5090293930 @default.
• W2115432999 date "2006-12-01" @default.
• W2115432999 modified "2023-10-06" @default.
• W2115432999 title "Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer" @default.
• W2115432999 cites W1876276942 @default.
• W2115432999 cites W1927722732 @default.
• W2115432999 cites W2050319891 @default.
• W2115432999 cites W2098333537 @default.
• W2115432999 cites W2120208453 @default.
• W2115432999 cites W2132737479 @default.
• W2115432999 cites W2135800076 @default.
• W2115432999 cites W2139963586 @default.
• W2115432999 cites W2140074016 @default.
• W2115432999 cites W2146384083 @default.
• W2115432999 cites W2214029008 @default.
• W2115432999 cites W2585390257 @default.
• W2115432999 cites W4293241248 @default.
• W2115432999 doi "https://doi.org/10.1200/jco.2006.06.5391" @default.
• W2115432999 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17135639" @default.
• W2115432999 hasPublicationYear "2006" @default.
• W2115432999 type Work @default.
• W2115432999 sameAs 2115432999 @default.
• W2115432999 citedByCount "462" @default.
• W2115432999 countsByYear W21154329992012 @default.
• W2115432999 countsByYear W21154329992013 @default.
• W2115432999 countsByYear W21154329992014 @default.
• W2115432999 countsByYear W21154329992015 @default.
• W2115432999 countsByYear W21154329992016 @default.
• W2115432999 countsByYear W21154329992017 @default.
• W2115432999 countsByYear W21154329992018 @default.
• W2115432999 countsByYear W21154329992019 @default.
• W2115432999 countsByYear W21154329992020 @default.
• W2115432999 countsByYear W21154329992021 @default.
• W2115432999 countsByYear W21154329992022 @default.
• W2115432999 countsByYear W21154329992023 @default.
• W2115432999 crossrefType "journal-article" @default.
• W2115432999 hasAuthorship W2115432999A5002951950 @default.
• W2115432999 hasAuthorship W2115432999A5003827285 @default.
• W2115432999 hasAuthorship W2115432999A5008682252 @default.
• W2115432999 hasAuthorship W2115432999A5010188774 @default.
• W2115432999 hasAuthorship W2115432999A5015961133 @default.
• W2115432999 hasAuthorship W2115432999A5020192186 @default.
• W2115432999 hasAuthorship W2115432999A5028916394 @default.
• W2115432999 hasAuthorship W2115432999A5029811877 @default.
• W2115432999 hasAuthorship W2115432999A5030497065 @default.
• W2115432999 hasAuthorship W2115432999A5042123072 @default.
• W2115432999 hasAuthorship W2115432999A5044957566 @default.
• W2115432999 hasAuthorship W2115432999A5047894550 @default.
• W2115432999 hasAuthorship W2115432999A5059365988 @default.
• W2115432999 hasAuthorship W2115432999A5065675425 @default.
• W2115432999 hasAuthorship W2115432999A5068051080 @default.
• W2115432999 hasAuthorship W2115432999A5068970824 @default.
• W2115432999 hasAuthorship W2115432999A5071432873 @default.
• W2115432999 hasAuthorship W2115432999A5076687894 @default.
• W2115432999 hasAuthorship W2115432999A5078164972 @default.
• W2115432999 hasAuthorship W2115432999A5090293930 @default.
• W2115432999 hasBestOaLocation W21154329991 @default.
• W2115432999 hasConcept C121608353 @default.
• W2115432999 hasConcept C126322002 @default.
• W2115432999 hasConcept C141071460 @default.
• W2115432999 hasConcept C143998085 @default.
• W2115432999 hasConcept C207103383 @default.
• W2115432999 hasConcept C2775930923 @default.
• W2115432999 hasConcept C2776694085 @default.
• W2115432999 hasConcept C2776755627 @default.
• W2115432999 hasConcept C2777063308 @default.
• W2115432999 hasConcept C2778850193 @default.
• W2115432999 hasConcept C2781190966 @default.
• W2115432999 hasConcept C2781413609 @default.
• W2115432999 hasConcept C44249647 @default.
• W2115432999 hasConcept C530470458 @default.
• W2115432999 hasConcept C71924100 @default.
• W2115432999 hasConcept C90924648 @default.
• W2115432999 hasConceptScore W2115432999C121608353 @default.
• W2115432999 hasConceptScore W2115432999C126322002 @default.
• W2115432999 hasConceptScore W2115432999C141071460 @default.
• W2115432999 hasConceptScore W2115432999C143998085 @default.

• next